![Cells | Free Full-Text | Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response Cells | Free Full-Text | Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response](https://www.mdpi.com/cells/cells-11-01959/article_deploy/html/images/cells-11-01959-g003.png)
Cells | Free Full-Text | Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response
![Highly Transparent Polyethylcyanoacrylates from Approved Eco-Friendly Fragrance Materials Demonstrating Excellent Fog-Harvesting and Anti-Wear Properties | ACS Applied Materials & Interfaces Highly Transparent Polyethylcyanoacrylates from Approved Eco-Friendly Fragrance Materials Demonstrating Excellent Fog-Harvesting and Anti-Wear Properties | ACS Applied Materials & Interfaces](https://pubs.acs.org/cms/10.1021/acsami.8b10717/asset/images/medium/am-2018-10717y_0009.gif)
Highly Transparent Polyethylcyanoacrylates from Approved Eco-Friendly Fragrance Materials Demonstrating Excellent Fog-Harvesting and Anti-Wear Properties | ACS Applied Materials & Interfaces
![Cells | Free Full-Text | Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response Cells | Free Full-Text | Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response](https://www.mdpi.com/cells/cells-11-01959/article_deploy/html/images/cells-11-01959-g002.png)
Cells | Free Full-Text | Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response
![Cells | Free Full-Text | Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response Cells | Free Full-Text | Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response](https://pub.mdpi-res.com/cells/cells-11-01959/article_deploy/html/images/cells-11-01959-ag.png?1655892456)